+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia



A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia



Haematologica 91(1): 24-31



Background and Objectives. Pegylated-asparaginase (PEG-ASP) has been traditionally used as a second-line preparation in children with acute lymphoblastic, leukemia (ALL) presenting with clinical allergy to native asparaginase (ASP) products. The main goal of the present study was to investigate the pharmacological effects of the administration of PEG-ASP given as a first-line product in children with ALL.Design and Methods.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011700691

Download citation: RISBibTeXText

PMID: 16434367


Related references

Pharmacological study on PEG-asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Blood 102(11): 207b, November 16, 2003

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97(2): 508-516, 2003

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatric Blood & Cancer 47(2): 141-146, 2006

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99(6): 1986-1994, March 15, 2002

High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. Jimd Reports 7: 103-108, 2013

The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience. Journal of Pediatric Hematology/Oncology 38(1): E16-E20, 2016

Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. Annals of Hematology 95(11): 1899-1901, 2016

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 109(10): 4164-4167, 2007

Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia. Drug and Chemical Toxicology 35(4): 463-466, 2013

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. Journal of Pediatric Hematology/Oncology 26(4): 217-226, 2004

L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer ChemoTherapy and Pharmacology 53(3): 204-208, 2003

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology 90(2): 120-124, 2015

Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). Journal of Pediatric Hematology/Oncology 33(8): 610-616, 2011

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. International Journal of Nanomedicine 1(3): 241-254, 2007